M. Chandhru , Karthikeyan Ramamurthy , Gokul Sudhakaran , Ki Choon Choi , M. Valan Arasu , Jesu Arockiaraj
{"title":"Aging-related epigenetic instability in lncRNAs and miRNAs mediates the development of hypertension","authors":"M. Chandhru , Karthikeyan Ramamurthy , Gokul Sudhakaran , Ki Choon Choi , M. Valan Arasu , Jesu Arockiaraj","doi":"10.1016/j.ejphar.2025.178150","DOIUrl":null,"url":null,"abstract":"<div><div>Hypertension is a complex, age-related condition that markedly elevates the risk of cardiovascular problems and mortality globally. With the aging global population, understanding the molecular foundations of hypertension is essential. Emerging evidence highlights the essential roles of non-coding RNAs, particularly Long non-coding RNAs and microRNAs, in regulating gene expression linked to vascular health and blood pressure control. This review examines the impact of aging on the expression and synthesis of key ncRNAs, which leads to malfunction in three pivotal systems: vascular smooth muscle cells, the renin-angiotensin-aldosterone system, and endothelial cells. Dysregulated ncRNAs impair nitric oxide bioavailability, enhance inflammation, and modify vascular tone, resulting in arterial stiffness and increased blood pressure. Crosstalk between lncRNAs and miRNAs, as exemplified by MALAT1–miR-145 and H19–let-7b, reveals a complex regulatory network that affects vascular remodeling and homeostasis. This review highlights new molecular targets for early diagnosis and therapeutic treatment of age-related hypertension, incorporating recent findings on miRNA and lncRNA interactions.</div></div>","PeriodicalId":12004,"journal":{"name":"European journal of pharmacology","volume":"1006 ","pages":"Article 178150"},"PeriodicalIF":4.7000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0014299925009045","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Hypertension is a complex, age-related condition that markedly elevates the risk of cardiovascular problems and mortality globally. With the aging global population, understanding the molecular foundations of hypertension is essential. Emerging evidence highlights the essential roles of non-coding RNAs, particularly Long non-coding RNAs and microRNAs, in regulating gene expression linked to vascular health and blood pressure control. This review examines the impact of aging on the expression and synthesis of key ncRNAs, which leads to malfunction in three pivotal systems: vascular smooth muscle cells, the renin-angiotensin-aldosterone system, and endothelial cells. Dysregulated ncRNAs impair nitric oxide bioavailability, enhance inflammation, and modify vascular tone, resulting in arterial stiffness and increased blood pressure. Crosstalk between lncRNAs and miRNAs, as exemplified by MALAT1–miR-145 and H19–let-7b, reveals a complex regulatory network that affects vascular remodeling and homeostasis. This review highlights new molecular targets for early diagnosis and therapeutic treatment of age-related hypertension, incorporating recent findings on miRNA and lncRNA interactions.
期刊介绍:
The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems.
The scope includes:
Behavioural pharmacology
Neuropharmacology and analgesia
Cardiovascular pharmacology
Pulmonary, gastrointestinal and urogenital pharmacology
Endocrine pharmacology
Immunopharmacology and inflammation
Molecular and cellular pharmacology
Regenerative pharmacology
Biologicals and biotherapeutics
Translational pharmacology
Nutriceutical pharmacology.